Savara Has Lost 30% Since December: JPMorgan Sees 146% Upside
JPMorgan initiated coverage of Savara (SVRA) with an Overweight rating and a $12 price target, implying 146% upside from its $4.88 close. The stock has fallen 30% since December, with FDA delays and wider losses. Analysts expect approval of Molbreevi on Nov. 22 to drive the stock's performance, with sales projections starting at $2.02M this year.
How this was made
The 30-second read
Why it matters
Analyst coverage adds a new data point for traders; the price target suggests a large upside if the drug clears regulatory hurdles.
Market read
New analyst rating and price target provide a fresh catalyst for Savara, with the upcoming FDA decision as the primary driver of price movement.
What to watch
The company's single-drug reliance and widening loss guidance increase downside risk.
Background
Savara is a clinical-stage biotech with one FDA‑pending product, Molbreevi. The FDA has delayed its decision to Nov. 22, creating uncertainty.
Ticker impact
JPMorgan initiated coverage with an Overweight rating and a $12 price target, 146% above the current price, providing new analyst guidance for Savara.
potential upside pressure if the FDA approves Molbreevi; downside risk if approval is delayed or denied
The coverage start is a fresh catalyst; the large upside target implies significant upside potential, but the stock remains highly dependent on the upcoming FDA decision.
Market effects
Positive sentiment may spill over to other biotech firms awaiting FDA decisions.
Limited to U.S. biotech sector; no broader regional effect.
Minimal global impact beyond niche biotech investors.
Counterpoint
The target assumes a successful FDA approval; a missed deadline could trigger a sharp sell-off.
Key entities
- companySavara
Biotech firm developing Molbreevi.
- analystJPMorgan
Initiated coverage with Overweight rating and $12 target.
